Answers are grounded in this paper and cite their sources.
The occurrence of agranulocytosis is a substantial hazard of the administration of clozapine, but this hazard can be reduced by monitoring the white-cell count. The increasing risk of agranulocytosis with age and the reduced incidence after the first six months of treatment provide additional guidelines for the prescription and monitoring of clozapine treatment in the future.
No takes yet. Share an insight, caveat, or question.
Alvir et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: